中性粒细胞与淋巴细胞比值及淋巴细胞最低点对 III 期非小细胞肺癌预后的预测价值。
Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer.
机构信息
School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH, USA.
Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, 1 Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia.
出版信息
Future Oncol. 2017 Jul;13(16):1405-1414. doi: 10.2217/fon-2017-0045. Epub 2017 Jul 7.
AIM
Studies have shown increased pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to be predictive of survival in various cancers. Our aim was to evaluate the prognostic role of such inflammatory markers in non-small-cell lung cancer (NSCLC).
METHODS
One hundred and sixty-three patients with stage III NSCLC who received definitive treatment were included. Survival analysis was performed using Kaplan-Meier method. Hazard ratios for overall and recurrence-free survival were estimated using Cox proportional hazards model.
RESULTS
Both neutrophil-to-lymphocyte >Q75 (4.5) and lymphocyte nadir values <Q25 (0.25) and their unified values were associated with 90% increased overall mortality risk (p = 0.040) and a nonsignificant 50% decreased recurrence-free survival risk.
CONCLUSION
Our exploratory analysis showed markers of systemic inflammation predicted survival outcomes in advanced NSCLC. Future prospective data analyses are needed to confirm this potential.
目的
研究表明，治疗前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值升高与多种癌症的生存相关。我们旨在评估这些炎症标志物在非小细胞肺癌（NSCLC）中的预后作用。
方法
纳入 163 例接受根治性治疗的 III 期 NSCLC 患者。采用 Kaplan-Meier 法进行生存分析。采用Cox 比例风险模型估计总生存和无复发生存的风险比。
结果
中性粒细胞与淋巴细胞比值＞Q75（4.5）和淋巴细胞最低值＜Q25（0.25）及其联合值与总死亡率增加 90%相关（p=0.040），而无复发生存率降低 50%无统计学意义。
结论
我们的探索性分析表明，全身炎症标志物可预测晚期 NSCLC 的生存结局。需要进一步前瞻性数据分析来证实这一潜在作用。
Zotero 插件